Overview
1. Executive Summary (Confidence: High)
The standard of care in oncology is rapidly evolving toward personalized therapy, yet access to necessary genomic testing remains a significant bottleneck. Hedera Dx addresses this by enabling hospitals to bring liquid biopsy testing in-house, bypassing the logistical and regulatory hurdles of centralized "send-out" testing. With its CE-IVD registered Hedera Prime software and the HP2 ctDNA test panel, the company provides a turn-key solution for molecular pathology labs. In May 2025, Hedera Dx secured €15 million in Series A funding to scale its operations globally, supported by its "Hedera Frame" initiative which generates real-world clinicogenomics evidence through large-scale clinical validation studies like EMPATHY NSCLC.
This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.